BCL2 and breast cancer: LncRNA-SNHG14 promotes trastuzumab resistance in HER2+ BC by altering the BCL-2/BAX signaling pathway; in addition, drug-resistant cells transfer lncRNA-SNHG14 to sensitive cells via sEVs, hence propagating trastuzumab resistance [174].